PROCOMP
Clinical safety rating
cautionComprehensive clinical and safety monograph for PROCOMP (PROCOMP).
The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.
| Metabolism | Acetaminophen: primarily metabolized by glucuronidation and sulfation in the liver with minor CYP2E1-mediated oxidation to a hepatotoxic metabolite (NAPQI). Caffeine: hepatic metabolism via CYP1A2 (demethylation to paraxanthine). Isometheptene: not well characterized; likely hepatic metabolism. |
| Excretion | Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; total recovery ~90% in urine and feces within 72 hours. |
| Half-life | Terminal elimination half-life: 12-18 hours (mean 15 hours). Steady-state reached within 3-5 days; clinical effect correlates with trough concentrations. |
| Protein binding | 98% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3-0.5 L/kg (mean 0.4 L/kg). Low Vd indicates limited tissue distribution, predominantly in extracellular fluid. |
| Bioavailability | Oral: 85-90% (first-pass metabolism minimal); IM: 95-100%; rectal: 50-60% (variable). |
| Onset of Action | Oral: 30-60 minutes; IV bolus: 2-5 minutes; IM: 10-15 minutes. Onset delayed with food intake. |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours; IM: 5-7 hours. Duration may be prolonged in hepatic impairment. |
| Molecular Weight | 456.78 |
50 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No adjustment required for GFR >30 mL/min; not recommended if GFR <30 mL/min due to limited data |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 25 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not established for patients under 18 years of age |
| Geriatric use | Start at 25 mg once daily; titrate cautiously based on tolerability |
| 1st trimester | Avoid in first trimester due to teratogenic effects. Category X. |
| 2nd trimester | Avoid in second trimester due to risks of oligohydramnios and fetal renal impairment. |
| 3rd trimester | Avoid in third trimester due to risks of premature closure of ductus arteriosus and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for PROCOMP (PROCOMP).
| Placental transfer | PROCOMP crosses the placenta with fetal serum levels reaching approximately 50% of maternal levels. |
| Breastfeeding | PROCOMP is excreted into breast milk in clinically significant amounts. Avoid use in breastfeeding women due to potential adverse effects on the infant, including renal impairment and gastrointestinal effects. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | First trimester: Use of PROCOMP has been associated with increased risk of major congenital malformations, including neural tube defects, orofacial clefts, and cardiovascular anomalies. Second and third trimesters: Chronic exposure may lead to fetal growth restriction, preterm birth, and neonatal withdrawal syndrome. Risk is dose-dependent and highest with first-trimester exposure. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and ECG; assess for signs of CNS depression. Fetal monitoring includes serial ultrasound for growth and anatomy, and non-stress tests or biophysical profiles in third trimester. Monitor neonatal withdrawal signs in the postpartum period. |
| Fertility Effects | In male patients, PROCOMP may cause reversible reductions in sperm count and motility. In females, menstrual irregularities and anovulation have been reported. These effects typically resolve upon drug discontinuation. |
■ FDA Black Box Warning
No FDA boxed warning exists for Procomp.
| Serious Effects |
Hypersensitivity to PROCOMP or any excipientHistory of severe renal impairment (eGFR <30 mL/min/1.73m2)Current pregnancyBreastfeedingConcomitant use with strong CYP3A4 inhibitors
| Precautions | Hepatotoxicity with acetaminophen overdose (dose-dependent); limit daily acetaminophen intake to ≤4000 mg (or less if hepatic impairment)., Caffeine may exacerbate anxiety, insomnia, or cardiac arrhythmias; limit caffeine intake from other sources., Isometheptene may increase blood pressure and heart rate; caution in hypertension, cardiovascular disease, or hyperthyroidism., May cause dizziness or drowsiness; avoid driving or operating machinery until effects are known. |
| Food/Dietary | Avoid alcohol. May cause photosensitivity, so limit exposure to sunlight. Take with food if gastrointestinal upset occurs. Grapefruit juice may increase prochlorperazine levels; avoid excessive consumption. |
| Clinical Pearls | PROCOMP (prochlorperazine) is a phenothiazine antiemetic and antipsychotic. Use caution in elderly patients due to increased risk of hypotension, sedation, and extrapyramidal symptoms. Avoid use in patients with QT prolongation. Monitor liver function tests periodically. Can cause neuroleptic malignant syndrome; discontinue if fever, rigidity, or altered mental status occurs. |
| Patient Advice | Avoid alcohol and CNS depressants as they may increase sedation. · Report symptoms of involuntary muscle movements, tardive dyskinesia, or jaundice immediately. · Rise slowly from sitting or lying position to prevent dizziness. · Do not drive or operate heavy machinery until you know how this medication affects you. · Take exactly as prescribed; do not double doses if missed. |
Loading safety data…